Robocath is set to embark on safety and efficacy studies of its R-one robotic catheterization system, supported by a fresh injection of funds from both new investors and existing shareholders. The €4.7m ($5.2m) round – led by M Capital and Normandie Participations, contributions from past investors Go Capital and NCI – will not only help see the company through the regulatory pathway, it should also take the French firm beyond the anticipated H1 2018 market launch of the technology and to the end of next year, Robocath CEO Pascal Guy told Medtech Insight.
News of the financing was announced during of the annual EuroPCR meeting, in Paris May 16-19, where Robocath is showcasing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?